'(De-)sensitization' vs. ' Uncoupling': what drives cardiomyopathies in the thin filament? Reply Dr Hwang's recent letter concerning our paper raises some very interesting points about the molecular mechanism of familial cardiomyopathy (HCM and DCM) due to mutations in the proteins of the thin filament and the key role of troponin.
In principle, such mutations could cause defects in force generation or force transmission, but so far all the mutations in thin filament proteins that have been investigated in detail indicate abnormal force production linked to abnormal Ca 2+ regulation. by TnI phosphorylation to thin filaments containing DCM or HCM mutations that uncouple this relationship. 3 All of these reagents act by binding to troponin; thus understanding how Ca 2+ and phosphorylation control contractility through troponin is the key to determining how thin filament cardiomyopathies are initiated.
There are severe practical problems in linking troponin structure with function, because the most important parts of the complex are intrinsically disordered and cannot be defined in terms of a static structure. These include the cardiac-specific N-terminus of cTnI (amino acids 1 -30) that contains the PKA phosphorylation sites (Serines 22 and 23), the so-called switch peptide of cTnI (148 -164), that plays a key role in the Ca 2+ -dependent switching on and off of the thin filament, and the C-terminus of troponin T (cTnT 3 280 -298) whose function is not known although it is likely to be located close to the regulatory region of troponin and may interact with the other two peptides. Protein nuclear magnetic resonance has been used to determine the structure of the missing peptides and their binary complexes with troponin C (TnC) in several states. sensitivity and not involve cTnI 1 -30, therefore, it would be uncoupled. The rationale for proposing this is the observation that we measure uncoupling and the effects of EMD57033 and EGCG in the in vitro motility assay (IVMA), where the Ca 2+ sensitivity of filament activation is very high (EC 50 0.1-0.3 mM), whereas the Ca 2+ sensitivity of contractility in skinned cardiac muscle in the phosphorylated and unphosphorylated states is 10 times lower. However, there seems no justification for a two-mechanism model. As described in our papers, Ca 2+ regulation of thin filaments occurs normally when measured by the IVMA and all the effects of phosphorylation, mutants, Ca 2+ sensitizers and desensitizers, and especially uncoupling and re-coupling on Ca 2+ sensitivity were consistently observed using the IVMA technique, and in the case of the small molecules, effects were shown to be fully reversible. In these studies, Ca 2+ sensitivity ranged between 0.04 and What we undoubtedly agree upon is the central role of troponin abnormalities in cardiomyopathy and the need to know much more about the structure and dynamics of the intrinsically disordered regulatory segments of the molecule. Not only is this necessary to provide a molecular mechanism for the physiological effects of TnI phosphorylation and mutations in thin filaments that cause cardiomyopathy, it is also essential to understand how small molecules can interact with this system. 12 This is clinically relevant since Ca 2+ sensitizers acting on TnC have been investigated as inotropic drugs, and our discovery of the ability of EGCG and similar compounds to reverse the uncoupling effect of DCM-causing mutations (and some HCM-causing mutations) points to potential therapies for familial cardiomyopathies.
